Faculty

Gabriela Chiorean, MD

Gabriela Chiorean, MD

Professor, Department of Medicine, Division of Oncology
Clinical Research Director

Mailing Address

Seattle Cancer Care Alliance
825 Eastlake Ave E, LG-465
Seattle, WA 98109-1023

Admin Contact

Lillianne Lui
206-606-6324
tklui@seattlecca.org

Specialty / Expertise

Colorectal, pancreatic and hepatobiliary cancers, as well as phase I novel therapeutics clinical trials

Research Interests

Early stage, phase 1/2 novel therapeutics clinical trials in pancreatic and gastrointestinal cancers, as well as translational research for biomarker discovery for early cancer detection and prevention

Current Research Projects

Phase 1 and 2 clinical and translational research in pancreatic and colorectal cancer

Training

Dr. Chiorean received her medical degree from University of Medicine and Pharmacy, Cluj-Napoca, Romania. Her residency was completed at William Beaumont Hospital, Royal Oak, MI. She was a post-Doctoral fellow in Hematology-Oncology at University of Minnesota, Minneapolis, MN.

Selected Publications

Ramanathan RK, Korn RL, Chiorean EG, Liu H, Von Hoff DD. Positron emission tomography (PET) as predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline. Ann Oncol 2016; 27(8): 1647-1648

Saif MW, Knost JA, Chiorean EG, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH. Phase I study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. Cancer Chemother Pharmacol 2016; 78(4):815-824

Deng L, Gu H, Nagana Gowda GA, Djukovic D, Chiorean EG, Raftery D. Combining NMR and LC/MS using backward variable elimination: metabolomics analysis of colorectal cancer, polyps, and healthy controls. Anal Chem 2016; 88(16): 7975-7983.

LoRusso PM, Gounder M, Jalal SI, Andre V, Prasad Kambhampati SR, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, Kauh J, Chiorean EG. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs 2017 Feb 4. PMID:28161886

Burstein H, Krilov L, Aragon-Ching J, Baxter N, Chiorean EG, Chow WA, de Groot JF, Devine SM, DuBois S, El-Deiry WS, Epstein AS, Heymach JV, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung NM, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 2017 Feb 1:JCO2016715292. PMID: 28148207.

Last updated: October 2018

Top